Leukopenia — Reduced White Blood Cell Counts

Clinically, leukopenia occurs when the total leukocyte count drops below standard laboratory reference thresholds, typically below 4,000 cells per microlitre of blood. White blood cells comprise several distinct functional subsets—including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. A deficit in any of these components lowers total counts, although neutropenia (a deficit of neutrophils) represents the most common and clinically dangerous form of leukopenia in cancer care.

In oncology, leukopenia is most frequently an iatrogenic consequence of cytotoxic chemotherapy, immunotherapy, or extensive radiation therapy targeting bone-marrow-rich sites. Cytotoxic antineoplastic drugs target rapidly dividing cells indiscriminately, temporarily suppressing the proliferative stem cells within the bone marrow. Alternatively, leukopenia can stem from direct neoplastic infiltration of the marrow compartment by haematologic malignancies or advanced metastatic solid tumours.

Recognising leukopenia is essential because it is a primary driver of treatment delays, hospital admissions, and life-threatening complications like febrile neutropenia. When white blood cell counts fall too low, ordinary signs of infection, such as pus formation or localised swelling, may not appear because there are insufficient immune cells to produce them. Fever is often the only warning sign. Prompt identification allows oncology teams to adjust drug schedules and provide preventative treatments, ensuring cancer therapy continues safely.

Leukopenia is diagnosed using a standard full blood count (FBC) with automated white blood cell differential. This laboratory test breaks down total leukocytes into specific lineages, establishing the Absolute Neutrophil Count (ANC). In complex or prolonged cases, clinicians may perform a peripheral blood film review or bone marrow biopsy to assess whether stem cell suppression or malignant marrow invasion is responsible.

Leukopenia is encountered across almost all cancer types treated with myelosuppressive chemotherapy, including breast, lung, ovarian, and gastrointestinal carcinomas. It is also particularly prevalent in primary haematological cancers such as acute and chronic leukemias, multiple myeloma, and non-Hodgkin lymphomas, where malignant marrow expansion directly suppresses healthy white blood cell generation.

Management centres on avoiding infection and helping marrow recover. Severe leukopenia often requires chemotherapy dose reductions or temporary treatment delays until counts normalize. Supportive interventions include granulocyte colony-stimulating factors (G-CSF), such as filgrastim or pegfilgrastim, which stimulate bone marrow to accelerate white blood cell production. Patients also receive prophylactic broad-spectrum antibiotics or antifungals, accompanied by clear self-monitoring guidelines.